TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Women's Adherence to Women-only, Home-based and Traditional Cardiac Rehabilitation (Cardiac Rehabilitation for Her Heart Event Recovery [CR4HER])
Brief Summary: The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.


Options:
A: Arm Label: Home-based training; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based training | Arm Label: Centre-based training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Centre-based training | Intervention Type: BEHAVIORAL; Name: Home-based training; Assigned to Arm(s): Home-based training | Intervention Type: BEHAVIORAL; Name: Centre-based training; Assigned to Arm(s): Centre-based training
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2
C: Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation
D: Arm Label: Treadmill group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: Exercise groups; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: home-based exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise groups, Treadmill group, home-based exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Women's Adherence to Women-only, Home-based and Traditional Cardiac Rehabilitation (Cardiac Rehabilitation for Her Heart Event Recovery [CR4HER])
Brief Summary: The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.


Options:
A: Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation
B: Arm Label: PATHway; Type: EXPERIMENTAL; Interventions: Behavioral: PATHway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PATHway; Assigned to Arm(s): PATHway
C: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: During IVF treatment women will be randomized into supplementation with a high or a low dose of Vitamin D Main outcome Laboratory pregnancy, live pregnancy at 12 weeks, Baby take home rate, OHSS Secondary outcome: 1. Pregnancy complications (pregnancy hypertension, SGA, Diabetes) 2.Thrombin generation


Options:
A: Arm Label: Zinc sulfate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: zinc sulfate | Arm Label: Healthy control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc sulfate; Assigned to Arm(s): Zinc sulfate
B: Arm Label: High dose Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Arm Label: Low dose Vitamin D; Type: SHAM_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): High dose Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): Low dose Vitamin D
C: Arm Label: Folic acid and zinc supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 5 mg folic acid and 30 mg elemental zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 5 mg folic acid and 30 mg elemental zinc; Assigned to Arm(s): Folic acid and zinc supplementation | Intervention Type: DRUG; Name: Placebo Comparator: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Resveratrol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resveratrol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo pills | Intervention Type: DIETARY_SUPPLEMENT; Name: Resveratrol; Assigned to Arm(s): Resveratrol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo pills; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: During IVF treatment women will be randomized into supplementation with a high or a low dose of Vitamin D Main outcome Laboratory pregnancy, live pregnancy at 12 weeks, Baby take home rate, OHSS Secondary outcome: 1. Pregnancy complications (pregnancy hypertension, SGA, Diabetes) 2.Thrombin generation


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary lifestyle intervention | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary lifestyle intervention; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: High dose Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Arm Label: Low dose Vitamin D; Type: SHAM_COMPARATOR; Interventions: Dietary Supplement: Ergocalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): High dose Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol; Assigned to Arm(s): Low dose Vitamin D
C: Arm Label: Resveratrol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Resveratrol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo pills | Intervention Type: DIETARY_SUPPLEMENT; Name: Resveratrol; Assigned to Arm(s): Resveratrol | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo pills; Assigned to Arm(s): Control
D: Arm Label: Experimental Healthy Lifestyle; Type: EXPERIMENTAL; Interventions: Other: Healthy Lifestyle | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Healthy Lifestyle; Assigned to Arm(s): Experimental Healthy Lifestyle

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Brief Summary: 350 patients with early leukemias were assigned to receive peripheral blood or bone marrow transplantation; the occurrence of acute and chronic graft versus host disease, survival, transplantation-related mortality, and relapse rates were compared.


Options:
A: Arm Label: Bone marrow transplantation; Type: OTHER; Interventions: Procedure: Bone marrow transplantation | Arm Label: Peripheral blood stem cell transplantation; Type: OTHER; Interventions: Procedure: Peripheral blood stem cell transplantation | Intervention Type: PROCEDURE; Name: Bone marrow transplantation; Assigned to Arm(s): Bone marrow transplantation | Intervention Type: PROCEDURE; Name: Peripheral blood stem cell transplantation; Assigned to Arm(s): Peripheral blood stem cell transplantation
B: Arm Label: gPCC-G (Gothenburg Person Centred Care) Group; Type: EXPERIMENTAL; Interventions: Other: gPCC (Gothenburg Person Centred Care) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: gPCC (Gothenburg Person Centred Care); Assigned to Arm(s): gPCC-G (Gothenburg Person Centred Care) Group
C: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Stepped Care | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stepped Care; Assigned to Arm(s): Stepped Care
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Reflexology | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Reflexology; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial on the Cardiovascular Effects of Lung Volume Reduction Surgery in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: A randomised controlled trial will be performed to evaluate the effects of lung volume reduction surgery (LVRS) in patients with COPD on systemic inflammation, oxidative stress, endothelial function, arterial stiffness and blood pressure. We hypothesize that LVRS will lead to a reduction of systemic inflammation, oxidative stress, arterial stiffness and blood pressure and to improved endothelial function.

For this purpose 30 patients with severe/very severe COPD (GOLD III-IV) and pulmonary emphysema who are to undergo LVRS will be randomised to one of two groups: group 1 receiving immediate LVRS and group 2 receiving LVRS after a delay of 3 months.

Measures of systemic inflammation, oxidative stress, endothelial function, arterial stiffness and blood pressure will be measured at baseline and 3 months after surgery and no surgery, respectively (group 2 receiving surgery only after a delay of 3 months will serve as control group) to investigate the effects of LVRS on the described outcomes.


Options:
A: Arm Label: Treatment plus Optimal Medical Therapy; Type: EXPERIMENTAL; Interventions: Device: Treatment plus Optimal Medical Therapy | Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal Medical Therapy | Intervention Type: DEVICE; Name: Treatment plus Optimal Medical Therapy; Assigned to Arm(s): Treatment plus Optimal Medical Therapy | Intervention Type: OTHER; Name: Optimal Medical Therapy; Assigned to Arm(s): Optimal Medical Therapy
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Intervention Type: DRUG; Name: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: Lung volume reduction surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung volume reduction surgery | Arm Label: No lung volume reduction surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): Lung volume reduction surgery
D: Arm Label: BLVR Treatment; Type: EXPERIMENTAL; Interventions: Biological: BLVR Treatment | Intervention Type: BIOLOGICAL; Name: BLVR Treatment; Assigned to Arm(s): BLVR Treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Association Between the Diet, the Composition of Microbiota of the Intestinal Tract, Human Health and Well-being
Brief Summary: Metabolic syndrome and thereby obesity is associated with low-grade systemic inflammation and it is likely that this is also the case in children (Ley et al., 2005). It has also been shown that the gut microbiota is different in obese individuals compared to normal weight individuals and that the microbiota seems to have a role in fat storage (Backhead et al, 2004).

Intervention study with overweight and normal weight school age children. The children will be randomised to receive selected probiotics or a placebo. Fecal and blood samples will be collected, and anthropometric measurements (weight, height, skin folds) will be recorded before and after the intervention. The dynamic of the microbiota of the GI will be monitored by molecular methods. Markers of intestinal inflammation (calprotectin) and permeability will be analysed. Blood samples will be analysed to evaluate how the intervention influence the systemic polarization of the immune response by means of cytokine analyses. Furthermore, blood pressure, blood lipid profile and early markers of metabolic syndrome will be evaluated. Hypotheses This study will examine if overweight in children is associated with a different intestinal microbiota and if a change in microbiota caused by probiotics can modify inflammation and risk factors for the metabolic syndrome.


Options:
A: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Diet with increased intake of rye bread, berries and fish | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Increased intake of whole grain and rye bread | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control diet with decreased intake of rye bread, berries and fish | Intervention Type: DIETARY_SUPPLEMENT; Name: Diet with increased intake of rye bread, berries and fish; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: Increased intake of whole grain and rye bread; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Control diet with decreased intake of rye bread, berries and fish; Assigned to Arm(s): C
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Ls-33; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Whole Grain Foods; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI
Brief Summary: This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients with chemo-refractory advanced or metastatic adenocarcinoma of stomach or lower esophagus (mGC).

There is a clear scientific rationale for the use of Sunitinib to treat patients with mGC. Despite recent therapeutic advances, the median overall survival (OS) in patients with mG is still ≤ 12 months. Therefore, newer agents with novel mechanisms of action are desperately needed for treatment of these patients.


Options:
A: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo
B: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
D: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI
Brief Summary: This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients with chemo-refractory advanced or metastatic adenocarcinoma of stomach or lower esophagus (mGC).

There is a clear scientific rationale for the use of Sunitinib to treat patients with mGC. Despite recent therapeutic advances, the median overall survival (OS) in patients with mG is still ≤ 12 months. Therefore, newer agents with novel mechanisms of action are desperately needed for treatment of these patients.


Options:
A: Arm Label: Olaparib+ paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Paclitaxel | Arm Label: Placebo+paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib+ paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Olaparib+ paclitaxel, Placebo+paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+paclitaxel
B: Arm Label: TAS-102+BSC; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo+BSC; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC
C: Arm Label: Physician choice chemotherapy+Best Supportive Care (BSC); Type: EXPERIMENTAL; Interventions: Drug: Irinotecan, Drug: Paclitaxel, Other: Best Supportive Care (BSC) | Arm Label: Avelumab+BSC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avelumab, Other: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Avelumab; Assigned to Arm(s): Avelumab+BSC | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Physician choice chemotherapy+Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Physician choice chemotherapy+Best Supportive Care (BSC) | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Avelumab+BSC, Physician choice chemotherapy+Best Supportive Care (BSC)
D: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Study for the Assessment of the Long-term Safety and Efficacy of Cx401 in Patients Taking Part in the FATT-1 Trial
Brief Summary: The purpose of this extension is to investigate and confirm the long-term (6 months) safety and efficacy of the preceding FATT-1 trial \[ClinicalTrials.gov identifier: NTC00475410\], which studied patients with perianal fistula treated having received adipose-derived adult stem cell (ASC)and/or fibrin glue.


Options:
A: Arm Label: ASCs; Type: N/A; Interventions: Drug: ASCs | Arm Label: Fibrin glue; Type: N/A; Interventions: Drug: Fibrin glue | Arm Label: ASCs + Fibrin Glue; Type: N/A; Interventions: Drug: ASCs | Intervention Type: DRUG; Name: ASCs; Assigned to Arm(s): ASCs | Intervention Type: DRUG; Name: Fibrin glue; Assigned to Arm(s): Fibrin glue | Intervention Type: DRUG; Name: ASCs; Assigned to Arm(s): ASCs + Fibrin Glue
B: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mesenchymal stromal cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stromal cells (MSC) for infusion | Intervention Type: DRUG; Name: Mesenchymal stromal cells (MSC) for infusion; Assigned to Arm(s): Mesenchymal stromal cells
D: Arm Label: Hematopoietic Stem Cell Transplant Regimen 2; Type: EXPERIMENTAL; Interventions: Biological: Hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: Hematopoietic stem cell transplantation; Assigned to Arm(s): Hematopoietic Stem Cell Transplant Regimen 2

Answer: A